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CD4 + CD25+ Foxp3+ T cellsMost of the therapeutic strategies to control multiple sclerosis are directed to immune modulation and
inﬂammation control. As heat shock proteins are able to induce immunoregulatory T cells, we investigated the
therapeutic effect of a genetic vaccine containing the mycobacterial hsp65 gene on experimental autoimmune
encephalomyelitis (EAE). Although pVAXhsp65 was immunogenic for mice with EAE and downmodulated speciﬁc
cytokine induction byMOG, therapy was not able to decrease clinical severity nor to modify immunologic parame-
ters in the CNS. These results indicate that hsp65, administered as a DNA vaccine, was not therapeutic for EAE.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is the most common inﬂammatory and
demyelinating disease of the central nervous system (CNS). It is esti-
mated that this disease affects up to two million people worldwide
but its distribution throughout the different geographical regions is
very uneven. MS is being particularly prevalent in temperate zones
and, contrarily, much less common in subtropical and tropical areas.
The interplay among factors as genetic background, environmental
conditions and socio-economic network seems to deﬁne this contrasting
incidence (Koch-Henriksen and Sorensen, 2011).
The generally accepted hypothesis is that the disease is triggered by
the activation of autoaggressive T cells speciﬁc for myelin antigens,
followed by an expanding neurodegenerative process (Zhang et al.,
1994; Compston and Coles, 2008). These cells cross the blood–brain
barrier (BBB), establish themselves at the CNS and mediate damage
against the central neurons, their myelin sheaths and also to their
axons (Fletcher et al., 2010). The interaction between different cells
and mediators of the immune system and a variety of components of
the CNS determines the pathogenesis of MS. Brieﬂy, T self-reactivelogia e Imunologia, Instituto de
otucatu, São Paulo, Distrito de
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ights reserved.cells are somehow activated in the periphery and have the potential
to differentiate into distinct effector T cell subsets as Th1 and Th17
(McFarland and Martin, 2007). These activated cells up-regulate
integrins, cross the BBB, encounter the cognate self-antigens presented
by resident or immigrant antigen presenting cells (APCs) in the CNS and
release their signature cytokines. These cytokines, together with
different cell types that are attracted to the inﬂamed region, cause direct
or indirect local damage (Barnett et al., 2006). Tc, Th2, B cells, macro-
phages and an array of soluble mediators additionally contribute to
local tissue destruction (Fletcher et al., 2010; Constantinescu et al.,
2011). Resolution of the inﬂammatory process is often partial
and is due to immunoregulatory mechanisms mediated by regulatory
T or NK cells (McGeachy et al., 2005; Hao et al., 2010). The
anti-inﬂammatory IL-10 cytokine has been largely associated with
these immunoregulatory mechanisms (McGeachy et al., 2005).
Much of the knowledge related to MS immunopathogenesis is orig-
inated from experimental autoimmune encephalomyelitis (EAE). This is
considered a very useful model to unravel the immunological interac-
tions throughout the disease and also to test potential therapeutical or
immunomodulatory drugs (Gold et al., 2006). Different from the
humandisease, EAE is deliberately induced by immunizationwith amy-
elin antigen associated with an adjuvant (Stromnes and Goverman,
2006; Seger et al., 2010; Zorzella-Pezavento et al., 2010). Most of the
drugs that are in current use or that are already being submitted to
clinical trials for MS treatment were validated through EAE studies.
The main licensed drugs for MS therapy include type 1 interferons
(Castro-Borrero et al., 2012), glatiramer acetate (Castro-Borrero et al.,
36 S.F.G. Zorzella-Pezavento et al. / Journal of Neuroimmunology 268 (2014) 35–422012), mitoxantrone (Hartung et al., 2002) and azathioprine (Casetta
et al., 2007). Many other disease modifying therapies are under clinical
trials as recently reviewed by Constantinescu et al. (2011).
Heat shock proteins (hsps) are a group ofmolecular chaperones that
are categorized under distinct families according to their molecular
weights. As the name suggests they can be up-regulated by stressing,
including heat, conditions. However, they are constitutively and abun-
dantly present in all living beings where they play many important
roles. One of the most interesting aspects of these proteins is their
high degree of conservation during evolution. Heat shock protein 60
(hsp60) is one of the most well studied members of the hsp family.
Hsp60 from different bacterial species, also referred as hsp65, displays
more than 95% sequence homology at both DNA and protein levels.
An overall 55% homology is detected by comparing human and bacterial
hsp60/65 (Grundtman et al., 2011). In addition, hsp60/65was described
as a dominant antigen during bacterial infections (Kaufmann et al.,
1991) but also as a target self-antigen in pathological autoimmunity
(van Eden et al., 2005).Therefore, the initially prevailing view was that
this protein was involved in autoimmunity due to molecular mimicry
with the human counterpart (Jones et al., 1993). Further knowledge
revealed, however, that this molecule is endowedwith strong immuno-
regulatory properties (van Eden et al., 2005; van Eden et al., 2007). As
recently reviewed by Coelho and Faria (2012), the preferential direction
of its effects will be determined by a diversity of factors as, for example,
route of delivery, appropriate peptides and time point of its administra-
tion during the pathology. It has been shown by us and other groups
that DNA vaccines containing the human or the mycobacterial hsp60/
65 gene is able to confer protection against the development of diabetes
and arthritis (Quintana et al., 2002; Quintana et al., 2003; Santos-Junior
et al., 2005; Santos Júnior et al., 2007). Recently we also observed that
this vaccine was able to decrease inﬂammation and modulate immune
response in EAE induced in Lewis rats (Zorzella-Pezavento et al., 2010).
Considering this previous anti-inﬂammatory potential,we investigated
the possible therapeutic effect of pVAXhsp65 on EAE development.
2. Materials and methods
2.1. Experimental design
Mice were initially submitted to EAE induction by immunization
with MOG in Complete Freund's Adjuvant (CFA). A treatment with 3
or 4 pVAXhsp65 doses was started 5 days later. Efﬁcacy of therapy
with pVAXhsp65 on EAE was evaluated by clinical follow-up (weight
variation and clinical score) and also by histopathological analysis of
the CNS. The immunoregulatory effect of pVAXhsp65 was checked by
speciﬁc induction of cytokines with MOG and rhsp65 and also by
analyzing the presence of regulatory T cells (Treg) in the CNS and
spleen. Non-immunized (named control) and pVAX (empty vector)
injected animals were included as control groups.
2.2. Animals
Female C57BL/6 mice (8–10 weeks old) were purchased from
CEMIB (UNICAMP, São Paulo, SP, Brazil). The animals were fed with
sterilized food and water ad libitum and were manipulated in
accordance with the ethical guidelines adopted by the Brazilian College
of Animal Experimentation. All experimental protocols were approved
by the local Ethics Committee (Ethics Committee for Animal
Experimentation, Medical School, Universidade Estadual Paulista).
2.3. Genetic vaccine construction and puriﬁcation
The vaccine pVAXhsp65 was derived from the pVAX vector
(Invitrogen, Carlsbad, CA, USA), previously digested with BamH I and
Not I (Gibco BRL, Gaithersburg, MD, USA) by inserting a 3.3 kb fragment
corresponding to the M. leprae hsp65 gene and the CMV intron A. Theempty pVAX vector was used as a control. DH5α E. coli transformed
with plasmid pVAX or the plasmid carrying the hsp65 gene (pVAXhsp65)
were cultured in LB liquid medium (Gibco BRL, Gaithersburg, MD, USA)
containing kanamycin (100 μg/ml). The plasmids were puriﬁed using
the Concert High Purity Maxiprep System (Gibco BRL, Gaithersburg,
MD, USA). Plasmid concentrations were determined by spectrophotome-
try at λ = 260 and 280 nm by using the Gene Quant II apparatus
(Pharmacia Biotech, Buckinghamshire, UK).
2.4. Treatment with pVAXhsp65
C57BL/6 mice already immunized withMOG plus CFA were injected
with 3 or 4 pVAXhsp65 doses (100 μg each) by intramuscular route
(quadriceps muscle). The ﬁrst dose was administered 5 days after EAE
induction and subsequent doses were administered 5 days apart.
Control groups received the same volume of saline or the same concen-
tration of pVAX (empty vector).
2.5. EAE induction
MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) was synthetized
by Proteimax, São Paulo, Brazil. EAE was induced as previously described
(Zorzella-Pezavento et al., 2013). Brieﬂy, mice were subcutaneously
immunized with 150 μg of MOG35–55 peptide emulsiﬁed in complete
Freund's adjuvant (CFA) containing 5 mg/ml of mycobacteria. Mice also
received 2 doses, 0 and 48 h after immunization, of 200 ng of Bordetella
pertussis toxin (Sigma Aldrich, St. Louis, MO, USA) intraperitoneally.
Animals were daily inspected and disease intensity was graded as: 0 —
no disease, 1 — limp tail, 2 — weak/partially paralyzed hind legs, 3 —
completely paralyzed hind legs, 4 — complete hind and partial front leg
paralysis, 5 — complete paralysis/death.
2.6. Isolation of mononuclear cells inﬁltrated in the CNS
Mice were anesthetized with ketamine/xylazine and perfused with
10 ml of saline solution. Brain and spinal cord sections (cervical, thorac-
ic and lumbar)were excised,macerated andmaintained in 4 ml of RPMI
medium (Sigma Aldrich, St. Louis, MO, USA) supplemented with 2.5%
collagenase D (Roche Diagnostics, Indianapolis, IN, USA) at 37 °C, 5%
CO2 incubator. Forty-ﬁve min later suspensions were washed in RPMI
and centrifuged at 450×g for 15 min at 4 °C. Cells were then re-
suspended in percoll (GE Healthcare, Uppsala, Sweden) 37% and gently
laid over percoll 70% in tubes of 15 ml. The tubes were centrifuged at
950×g for 20 minwith centrifuge breaks turned off. After centrifugation
the ring containing mononuclear cells was collected, washed in RPMI
and centrifuged at 450×g for 5 min. Cellular suspensions were then
re-suspended in complete RPMI medium, counted and analyzed.
2.7. Spleen and CNS cell culture conditions
Mice with EAE treated with 3 or 4 pVAXhsp65 doses were eutha-
nized 30 days after EAE induction. Spleen and CNS-isolated cells were
collected and adjusted to 5 × 106 cells/ml and 2 × 105 cells/ml,
respectively. Cells were cultured in complete RPMImedium (RPMI sup-
plemented with 5% of fetal calf serum, 20 mM glutamine and 40 IU/ml
of gentamicin). Spleen cells were stimulated with MOG (20 μg/ml),
rhsp65 (10 μg/ml) or Concanavalin A - Sigma Aldrich (10 μg/ml).
CNS-isolated cells were re-stimulated in vitro with MOG (50 μg/ml) or
rhsp65 (10 μg/ml). Cytokine levels were evaluated 48 h later by
enzyme-linked immunosorbent assay (ELISA) in culture supernatants
using IFN-γ and IL-10 BD OptEIA Sets (Becton Dickinson, San Jose, CA,
USA) and IL-6, IL-17 and TNF-α Duosets (R&D Systems, Minneapolis,
MN, USA). The assays were performed according to the manufacturer's
instructions.
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Spleen cells were collected and the red blood cells were lysed with
Hank's buffer containing NH4Cl. Mononuclear cells inﬁltrated in the
brain and spinal cord were isolated as described before and adjusted
to 2.5 × 106 cells/100 μl. Spleen and CNS inﬁltrating cells were then in-
cubatedwith 0.5 μg of ﬂuorescein isothiocianate (FITC) anti-mouse CD4
(clone GK1.5) and 0.25 μg of allophycocyanin (APC) anti-mouse CD25
(clone PC61.5) for 20 min at room temperature. A staining for Foxp3
was then performed utilizing the phycoerythrin (PE) anti-mouse/rat
Foxp3 Staining Set (eBioscience, San Diego, CA, USA) according to the
manufacturer's instructions. After incubation, the cells were ﬁxed in
paraformaldehyde 1%. The cells were analyzed by ﬂow cytometry
using the FACSCalibur (Becton Dickinson, San Jose, CA, USA) and BD
CellQuest Pro software (Becton Dickinson, San Jose, CA, USA).2.9. Evaluation of inﬂammatory inﬁltrates in the CNS
A histological analysis was performed in the CNS at the 30th day
after EAE induction. After euthanasia and blood withdrawal, brain and
lumbar spinal cord samples were removed and ﬁxed in 10% formalde-
hyde. Tissues were dehydrated in graded ethanol and embedded in a
100% parafﬁn block. Serial sections with 5 μm thickness were cut and
stained with hematoxylin and eosin. Five photomicrographs were ob-
tained by each animal with a Nikon microscope.2.10. Statistical analysis
Data were expressed as mean ± SE. Comparisons between groups
were made by one way ANOVA with post-hoc Holm–Sidak test for pa-
rameters with normal distribution, and by Kruskal–Wallis followed by
a post hoc Dunn's test for parameterswith non-normal distribution. Sig-
niﬁcance level was p b 0.05. Statistical analysis was accomplished with
SigmaStat for Windows v 3.5 (Systat Software Inc).Control
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Fig. 1. Immunogenicity of pVAXhsp65 inmicewith EAE. C57BL/6micewere submitted to EAE
after EAE induction. IFN-γ (a), TNF-α (b), IL-6 (c), IL-17 (d) and IL-10 (e) productionwas assaye
(25–75% ranges) of 6 mice and representative of two independent experiments. *represents th3. Results
3.1. DNA vaccine containing the mycobacterial hsp65 gene is immunogenic
for mice with EAE
Homologous prime-boost strategies employing 3 or 4 doses of
pVAXhsp65 were similarly able to induce a speciﬁc immune response
against hsp65 in mice with EAE. Spleen cells re-stimulated in vitro
with rhsp65 produced high levels of IFN-γ (Fig. 1a) and IL-10 (Fig. 1e)
in comparison to the EAE group. This increase was not observed in
the group injected with pVAX (empty vector). The levels of TNF-α
(Fig. 1b), IL-6 (Fig. 1c) and IL-17 (Fig. 1d) in these cultures were also
elevated but they were similar to the ones found in the EAE group.
3.2. MOG-speciﬁc immunity is downmodulated by treatment with
pVAXhsp65
Treatment with pVAXhsp65 signiﬁcantly reduced the production of
IFN-γ (Fig. 2a), IL-6 (Fig. 2b) and IL-17 (Fig. 2c) by spleen cells re-
stimulated in vitro with MOG. IL-10 levels (Fig. 2d) in these cultures
were slightly lower than the levels found in the EAE control group;
however these differences were not signiﬁcant. A very similar proﬁle
of cytokine production was observed when the cultures were stimulat-
edwith ConA (Fig. 3). In both cases, the control EAE group injectedwith
the empty vector (pVAX) showed no immunomodulation.
3.3. Clinical disease severity is not improved by pVAXhsp65 treatment
The EAE control group, comprising C57BL/6 mice immunized
with MOG but not treated, developed the ﬁrst EAE signs 12 days
after disease induction. The maximal degree of paralysis, indicating
an acute phase, occurred around day 16, when the average clinical
score reached 2.0. From this time on the animals showed a decrease
in the clinical score, partially recovering from paralysis. However the
recovery was not complete and the disease stabilized around day 22X pVAXhsp65 3d pVAXhsp65 4d
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Fig. 2. Effect of therapeutical vaccination with pVAXhsp65 on MOG-speciﬁc immune response. C57BL/6 mice were submitted to EAE induction and then injected with 3 or 4
pVAXhsp65 doses. Cytokine production was tested 30 days after EAE induction. IFN-γ (a), IL-6 (b), IL-17 (c) and IL-10 (d) production was assayed in spleen cell cultures re-stimulated
in vitro with MOG. Data were presented as mean ± SE or median (25–75% ranges) of 6 mice and representative of two independent experiments. * represents the difference between
immunized and control group. p b 0.05.
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did not inﬂuence onset, duration or disease severity (Fig. 4a). Varia-
tion in body weight showed an expected course characterized by aControl
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covery was observed when the animals achieved the chronic disease
phase (Fig. 4b).Control
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Cells isolated from the CNS obtained from mice with EAE produced
high levels of TNF-α (Fig. 5b), IL-6 (Fig. 5c) and IL-10 (Fig. 5d), but
much lower levels of IFN-γ (Fig. 5a), in response to in vitro stimulation
with hsp65. Treatmentwith pVAXhsp65or its control, the empty vector,
did not alter this pattern. These cytokines were also induced by MOG0
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3.5. Quantiﬁcation of Foxp3+ T cells
The frequency of CD4 + CD25 + Foxp3+ T cells was evaluated in
the spleen and also in the mononuclear cells isolated from the CNS. A0
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groups in comparison to the control group (not submitted to EAE induc-
tion). Therefore, previous immunization with the vaccine or vector
injection did not modify Treg frequency. Contrasting with the small
increment of Treg cells in the lymphoid peripheral organ, a very high
proportion, around 25%, of the CNS inﬁltrating mononuclear cells was
Foxp3+ T cells (Fig. 6b). Treatment with the vector or the DNA vaccine
did not change the Foxp3+ T cells frequency in this target organ.
3.6. Inﬂammation is not affected by treatment with pVAXhsp65
Typical lesions, characterized by an intense perivascular inﬂammatory
inﬁltrate were observed in the brain (Fig. 7a, b and c) and lumbar spinal
cord (Fig. 7d, e and f). A visual inspection indicated that treated and
non-treated animals presented comparable degrees of inﬂammation.
4. Discussion
In this investigation we evaluated if the treatment with a DNA
vaccine containing the hsp65 gene fromMycobacterium leprae could im-
prove the clinical condition ofmicewith experimental encephalomyelitis.
This approach was based on the widely accepted concept that heat shock
proteins are potent immunomodulatory molecules (Keijzer et al., 2012).
Hsps are ubiquitous self-antigens that are highly expressed in inﬂamed
tissues. The prokaryotic counterparts, that are immunodominant anti-
gens, display large areas of sequence homology with the human hsps.
Even though this homology can trigger an autoimmune disease (Rajaiah
and Moudgil, 2009) it can also induce T cell regulation of chronic
inﬂammation (Hauet-Broere et al., 2006).
We initially examined the characteristics of the speciﬁc immune
response induced by immunization with 3 or 4 pVAXhsp65 doses in
mice whose encephalomyelitis was already induced. These pVAXhsp65
immunized animals exhibited a clear cellular immune response. Spleen
cells from immunized animals produced high levels of IFN-γ and IL-10;
these levels were similar to the ones found in normal (without EAE)
immunized mice (not shown). The levels of TNF-α, IL-6 and IL-17 were,
however, similar to the ones produced by the EAE control group. Interest-
ingly, the control EAE group also presented a recall response to in vitroc
f
l/ EAE pVAXhsp65 / EAE
tted to EAE induction and then injected with 4 pVAXhsp65 doses. Brain (ﬁgures a, b, c) and
ice with EAE (b, e) ormice treatedwith 3 pVAXhsp65 doses (c, f) were evaluated 30 days
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and IL-10 and also elevated levels of IL-6 and IL-17. A possible explanation
for these is the presence of hsp65 in the CFA that is used in disease
induction (Wong et al., 2003).
The regulatory ability of hsp65 was clearly observed in this investiga-
tion. The treatmentwith both therapeutic protocols (3 and 4DNA vaccine
doses) downmodulated the production of encephalitogenic cytokines by
spleen cells stimulated with MOG. The production of IFN-γ, TNF-α, IL-6
and IL-17 was signiﬁcantly smaller in these cultures, in comparison to
cultures from EAE non-treated group. Generally, the reduction detected
in the group treated with 4 doses was more accentuated than the one
observed in animals treated with 3 doses. This immunomodulatory effect
was also detectablewhen spleen cellswere stimulatedwith the polyclon-
al activator ConA, suggesting the activation of an extensivemechanism of
immunoregulation. The treatment with the empty vector did not trigger
this effect, indicating that is was related to the hsp65 gene. This
pVAXhsp65 downmodulatory effect over some pro-inﬂammatory cyto-
kines was already observed by our group in experimental autoimmunity
models (Santos-Junior et al., 2005; Zorzella-Pezavento et al., 2010).
Unexpectedly, this accentuated immunomodulatory activity was
not associated with any improvement in the clinical status of the
animals. Treated mice showed body weight loss and clinical scores
very similar to non-treated animals. pVAXhsp65 treatment was also
not able to quantitatively modify the CNS inﬂammatory process. These
ﬁndings also contrasted with the previous experience of our and other
groups. The therapeutic anti-inﬂammatory potential of this kind of con-
struction was already well characterized in various experimental
models as arthritis (Santos-Junior et al., 2005), tuberculosis (Silva
et al., 2005), hypersensitivity associated with esquistosomiasis (Frantz
et al., 2011) and, more recently, also in a model of allergy (Fonseca
et al., 2012). In relation to MS and its corresponding experimental
model there are no reports designed to investigate the beneﬁt of this
molecule as a therapeutical measure. As we already demonstrated
that a prophylactic immunization with pVAXhsp65 was able to signiﬁ-
cantly decrease brain inﬂammation in a rat EAE model (Zorzella-
Pezavento et al., 2010), we could think that pVAXhsp65 is more potent
to avoid naïve cell-priming than to control already activated T cells.
There is yet no direct experimental proof that this is the reason of this
unsuccessful therapy. This possibility is, however, reinforced by the
ﬁndings of Korn et al. (2007). These authors elegantly demonstrated
that Foxp3+ cells isolated from the CNS were effective in suppressing
naïve MOG-speciﬁc T cells but failed to control CNS-derived encephali-
togenic T effector cells that secreted IL-6 and TNF-α.
It is also important to consider that EAE in Lewis rats and in C57BL/6
mice present very distinct proﬁles of progression. In Lewis rat EAE is
characterized by a monophasic pathology with little demyelination
and edema in the CNS that is followed by total recovery after an acute
episode. Otherwise, EAE in C57BL/6 mice is a chronic-progressive dis-
ease associated with demyelination and axonal damage (Gold et al.,
2006). In this scenario, we could think that immunomodulatory cells
and/or mediators elicited by pVAXhsp65 probably found a refractory
environment in the CNS of C57BL/6 sick mice. The work of Korn et al.
(2007) supports this possibility.
The immunoregulatory ability of hsp65 has been attributed to differ-
ent mechanisms as tolerance induction, deviation of Th1 to Th2 polariza-
tion, suppression of Th17, apoptosis of pathogenic T cells and expansion/
activation of regulatory T cells as Tr1 and Th3 (Quintana et al., 2002;
Ulmansky et al., 2002; Satpute et al., 2007; Moudgil and Durai, 2008;
Rajaiah andMoudgil, 2009; Coelho and Faria, 2012). Interestingly, we ob-
served that immunization with pVAXhsp65 not only signiﬁcantly
downmodulated IL-17 speciﬁcally induced by MOG but also decreased
the production of other encephalytogenic cytokines as IFN-γ and IL-6.
These three cytokines have been described as highly encephalitogenic
(Fletcher et al., 2010; Jadidi-Niaragh andMirshaﬁey, 2011). It is therefore
tempting to speculate that downmodulation of the speciﬁc autoimmune
response is occurring but is not reaching the CNS. This possibility is, atleast partially, supported by our data obtained from analysis of the CNS
immunity. In this case, the previous vaccination did not modify the
MOG speciﬁc cytokine induction. Alternatively, we could think that this
type of construction (genetic vaccine) and the employed route of admin-
istration are not indicated to induce tolerance and immunoregulation. In
line with this possibility, it is widely described that genetic vaccines
administered by intramuscular route induce mainly Th1 and Tc effector
cells (Silva et al., 2009). This was clearly exempliﬁed by investigations
that demonstrated the induction of protection against experimental
tuberculosis by this vaccine (Bonato et al., 2004; de Paula et al., 2007).
However, our own experience indicated that this genetic construction
was able to protect mice against experimental arthritis and diabetes
(Santos-Junior et al., 2005; Santos Júnior et al., 2007; Santos Junior et al.,
2009). As the ability of this vaccine to protect against EAE in both mice
and rat (Zorzella-Pezavento et al., 2010) is clearly more discrete, we pos-
tulate that the characteristics of experimental encephalomyelitis could
make it more resistant to immunomodulation by pVAXhsp65. Factors as
hsp60 expression at the CNS, permeability of the BBB and type of regula-
tory T cell able to inﬁltrate in this target tissuemust be evaluated to better
understand the meaning of this result.
The evaluation of Foxp3+T cells in the spleen indicated that the EAE
development itself was already associated with a signiﬁcant increase in
the percentage of these cells. The therapeutic vaccination with
pVAXhsp65, however, did not increase the percentage of this type of
regulatory cell in the spleen. As the downmodulation of encephalito-
genic cytokines is occurring in the absence of an increase in Foxp3+
cells in spleen, it is possible that other T cell regulatory subsets are
being activated. The presence of hsp65-reactive T cells presenting a reg-
ulatory potential has been described mainly in experimental arthritis
(Tanaka et al., 1999; Prakken et al., 2001; Kamphuis et al., 2005).
Some studies have also suggested that hsps are antigens seen by natural
regulatory T cells (Nishikawa et al., 2005). However, in our work, in
mice immunized with pVAXhsp65 there was no increase of nTreg
cells. The contribution of hsp65-speciﬁc T cells for both, pathogenesis
and immunoregulation during EAE and MS is not well established.
Only a few reports were published in this area suggesting that hsp60
is expressed in brain cells (Selmaj et al., 1992) and that hsp60 speciﬁc
clones are present in the brain (Quintana et al., 2012). Altogether
these results indicate that hsp65 administered as a genetic vaccine
is able to downmodulate immunity against MOG but this effect is not
associated with a protective activity against EAE development.
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